The Journal of Allergy and Clinical Immunology: In Practice
Original ArticleLow Cross-Reactivity Between Cisplatin and Other Platinum Salts
Section snippets
Methods
We conducted a retrospective, descriptive, single-center study from September 2002 to April 2016 at the Dermatology Department of Dijon University Hospital, France. Patients coming for a dermato-allergology consultation for immediate hypersensitivity reactions to PS were included. An immediate reaction to PS was defined as a reaction that occurs during the infusion or within 1 hour after the infusion of one of the 3 PS (CA, OX, or CI). Skin tests were performed after a minimum of 4 to 6 weeks
Patients
During the 14-year study period, 184 patients had investigations for hypersensitivity reactions to PS. Among these patients, 29 were not analyzed because they had a delayed rather than immediate reaction. Finally, 155 remaining patients with immediate hypersensitivity were included (see Figure 1). Patients' clinical data are summarized in Table I.
Treatments and hypersensitivity reactions
The suspected PS was CA in 64 cases, OX in 87 cases, and CI in 4 cases. The median number of courses administered until the reaction occurred was 9
Discussion
Hypersensitivity to PS was first described by Hunter et al32 in 1945 among employees working in a refinery. Since then, the incidence of hypersensitivity has risen because of the widespread use of PS in many cancers treatments. Skin testing has proven to be helpful in the diagnosis of IgE-mediated hypersensitivity to a PS.22, 25, 29
We present here a study with a large number of patients tested after immediate hypersensitivity to PS. Our study included 155 patients with the same baseline
Acknowledgment
We thank the nurses for consultations and the secretaries of the Dermatology Department, Dijon University Hospital, Dijon, France, the staff of the archives of Centre Georges-François Leclerc, Dijon, France, and Mr. Philip Bastable, Research Unit at Dijon University Hospital.
References (49)
- et al.
Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization
J Allergy Clin Immunol Pract
(2014) - et al.
Head and neck cancer in the elderly: an overview on the treatment modalities
Cancer Treat Rev
(2009) - et al.
Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients
Gynecol Oncol
(2006) - et al.
Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients
Eur J Cancer
(2005) - et al.
Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital
Gynecol Oncol
(2007) - et al.
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
Gynecol Oncol
(2011) - et al.
Diagnostic and predictive value of skin testing in platinum salt hypersensitivity
J Allergy Clin Immunol
(2007) - et al.
Skin testing in the evaluation and management of carboplatin-related hypersensitivity reactions
J Allergy Clin Immunol Pract
(2015) - et al.
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy
Gynecol Oncol
(2002) - et al.
Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases
J Allergy Clin Immunol
(2008)
Clinical features and severity grading of anaphylaxis
J Allergy Clin Immunol
Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin
Gynecol Oncol
Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin
Ann Allergy Asthma Immunol
[Hypersensitivity to platinum salts and taxanes: the value of skin tests and tolerance induction procedures]
Ann Dermatol Venereol
Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy
J Allergy Clin Immunol Pract
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin
Gynecol Oncol
Death from anaphylaxis to cisplatin: a case report
Gynecol Oncol
Immediate hypersensitivity reaction to chemotherapeutic agents
J Allergy Clin Immunol Pract
A new practical desensitization protocol for oxaliplatin-induced immediate hypersensitivity reactions: a necessary and useful approach
J Investig Allergol Clin Immunol
Hypersensitivity reaction to carboplatin during treatment for ovarian cancer: successful resolution by replacement with cisplatin
Tumori
Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan
Int J Clin Oncol
Cellular and molecular pharmacology of oxaliplatin
Mol Cancer Ther
The resurgence of platinum-based cancer chemotherapy
Nat Rev Cancer
Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience
Oncology
Cited by (0)
No funding was received for this work.
Conflicts of interest: The authors declare that they have no relevant conflicts of interest.